The National Oncology Network, which will be implemented in phases starting April 1, 2025, is changing the way oncology care is organized, but its significance extends beyond the model of service delivery itself. For the market, this serves as a catalyst for restructuring relationships between treatment centers, payers, technology providers, and private operators. The growing importance of coordination, quality measurement, and standardization of patient pathways will influence investment decisions in the areas of radiation therapy and diagnostic imaging.
The most important business question, therefore, is not merely: who will be included in the network? What matters more is how the criteria for competing for contracts, partnerships, and a position within the regional oncology ecosystem will change. For healthcare providers and investors, the National Oncology Network means the need to analyze the market not only through the lens of available equipment, but also in terms of organizational capabilities, data quality, and collaboration among entities.
The network model strengthens the role of coordination in diagnostics, patient referral for further treatment, and monitoring of organizational outcomes. From a market perspective, this means shifting the focus from individual procedures to the efficiency of the entire patient care process. Centers participating in the National Oncology Network will be evaluated not only on the basis of service availability but also on their ability to operate within a structured model of collaboration.
In practice, referral flows, the timeliness of tests, the interoperability of IT systems, and access to specialized expertise are becoming increasingly important. For entities operating in radiation therapy and diagnostic imaging, this signals that a competitive advantage lies in one’s role within the patient pathway, rather than solely in possessing a specific technology.
This change may also lead to a clearer differentiation of the functions of healthcare facilities. Some providers will focus on procedures requiring a high level of specialization, while others will focus on rapid diagnostics, monitoring, or performing tests close to the patient’s place of residence. Such differentiation has implications for investments, resource planning, and models of cooperation with private partners.
The National Oncology Network is introducing monitoring of quality and organizational indicators. However, the extent to which these will influence the funding of services depends on the contracting and billing rules established by the National Health Fund (NFZ). The value of a healthcare provider will increasingly be assessed in terms of its ability to ensure process continuity, accurate reporting, and efficient information exchange with other entities. This does not automatically mean a reduction in competition, but rather a shift in its foundations.
In such an environment, analyzing local relationships between hospitals, cancer centers, diagnostic laboratories, and outpatient facilities is of particular importance. It is important to identify where bottlenecks arise, which tests are performed outside the region, and in which segments it is possible to build lasting partnerships.
Radiation therapy remains a highly capital-intensive segment, heavily dependent on the availability of specialized staff, the stability of technical processes, and coordination with diagnostics and surgical treatment. In a network model, the ability to integrate radiation therapy into a seamless pathway between diagnosis, patient selection, and follow-up care becomes crucial.
For operators, this means they must view investments more broadly than simply through the lens of equipment purchases. It is essential to assess the demographic potential of a given area, the structure of patient inflow, the actual availability of staff, relationships with referring centers, and the ability to effectively utilize the infrastructure over the long term.
Investment risk may increase where the decision to expand capacity is based solely on observations of local demand. Equally important are regional patient flows, the development plans of other providers, and the scope of services provided by the nearest referral centers. For this reason, an analysis of the radiation therapy market should cover both the supply of services and the organization of the entire referral network.
First and foremost, it is worth verifying whether the planned investment addresses an actual gap in access or merely duplicates existing supply. It is also important to develop an operational model: work schedules, maintenance arrangements, personnel management, and collaboration with diagnostic providers.
A high-quality investment decision should take into account scenarios involving changes in financing, the location of competing projects, and the pace of public infrastructure development. A helpful point of reference may be a report on the market for diagnostic imaging and radiation therapy services in Poland, which allows decisions to be placed within a broader sectoral context.
In diagnostic imaging, the importance of timeliness, the quality of reports, the consistency of documentation, and the ability to share results between facilities is growing. For the market, this does not merely mean greater demand for examinations. Above all, it signifies the need to establish processes that minimize delays and facilitate decision-making by centers participating in the oncology care pathway.
Laboratories operating as independent providers can benefit from collaborating with larger entities, provided they are able to meet their partners’ operational and informational requirements. Advantages may include efficient handling of referrals, predictable turnaround times, access to appropriate specialists, and a standard of communication that allows results to be quickly utilized in subsequent stages of the process.
At the same time, the network model may increase pressure to consolidate or formalize partnership relationships. Smaller laboratories that fail to build lasting ties with referring centers may experience greater volatility in demand. This does not necessarily mean losing market share, but it does require a precise definition of the facility’s role within the local ecosystem.
The readiness assessment should not be limited to the technical condition of the equipment. It is essential to analyze the process from the receipt of a referral to the delivery of results, as well as the quality of the data used in reporting. The ability to identify sources of delays and recurring operational issues is of particular importance.
Private operators can play several roles: provider of diagnostic tests, infrastructure partner, entity delivering specific services, or investor developing specialized centers. However, their position will depend on their ability to cooperate with the public system and to tailor their offerings to actual regional needs.
A key strength of the private sector may be operational flexibility, the rapid implementation of organizational changes, and the ability to build specialized teams. However, these advantages cannot replace the need for effective management of relationships with public partners. In a coordination-based model, the predictability of service delivery and adherence to agreed-upon processes become paramount.
It is also worth noting that not every supply gap justifies a standalone private investment. In many locations, contractual cooperation, shared use of resources, or the development of services supporting existing facilities may be more effective. Such a decision should be based on an analysis of needs, competition, regulatory barriers, and potential sources of funding.
The strategy should combine demand data with an analysis of market structure. Population potential alone is not sufficient to assess a project’s viability. It is essential to understand where patients are currently being diagnosed, where they proceed to the next stages of their care pathway, and which entities influence the flow of care.
In Polish analyses, research conducted by, among others, the independent research agency Hume’s Institute can be helpful. It is worth cross-referencing primary data with information on the structure of supply, planned investments, the availability of personnel, and the preferences of decision-makers.
PMR Market Experts publishes periodic reports that support the assessment of sector trends, competitors’ positions, and development directions for specific healthcare segments. For projects requiring the evaluation of multiple options, it is particularly important to combine market data with decision-making workshops and financial scenarios.
It is worthwhile to use tools such as market forecasts, as they allow for an assessment of the consequences of various assumptions regarding demand, competition, and the financial environment. For large-scale projects, specialized consulting focused on selecting a market entry model, a partner, or a location may also be useful.
The National Oncology Network reinforces the importance of organizational quality and collaboration among stakeholders. In radiation therapy and diagnostic imaging, a competitive advantage will depend on the ability to operate effectively across a broader spectrum of services, rather than solely on technical resources.
If you are planning to invest in radiation therapy, diagnostic imaging, or developing a partnership with a private operator, it is advisable to contact PMR Market Experts to base your decision on a reliable market analysis, development scenarios, and practical strategic recommendations.
OTHER BLOG POSTS: